Effectiveness of heparin in preventing thrombin generation and thrombin activity in patients undergoing coronary intervention

Am Heart J. 1999 Feb;137(2):250-7. doi: 10.1053/hj.1999.v137.91541.

Abstract

Background: Thrombus is important in the pathophysiology of several complications of angioplasty, including abrupt closure and restenosis. Levels of prothrombin fragment F1.2 and fibrinopeptide A reflect thrombin generation and activity. The effect of angioplasty on levels of these markers is unclear.

Methods: Patients undergoing either balloon angioplasty (n = 30) or directional atherectomy (n = 9) were treated with heparin to maintain an activated clotting time of >300 seconds. Levels of F1.2, fibrinopeptide A, and thrombin-antithrombin complex were measured in the coronary sinus and coronary artery before and after intervention. Angiograms were reviewed for lesion morphologic characteristics and dissection.

Results: There was no evidence for thrombin generation or increased thrombin activity after angioplasty regardless of lesion morphologic characteristics, dissection, type of intervention, or blood sampling site. In fact, coronary sinus concentrations of F1.2 decreased after intervention (median 0.31 nmol/L; 25th percentile 0.26 nmol/L, 75th percentile 0.37 nmol/L) before intervention to 0.23 nmol/L (25th percentile 0.19 nmol/L, 75th percentile 0.34 nmol/L) after intervention (P =.002).

Conclusions: Angioplasty performed in the presence of adequate heparin inhibited thrombin even when there was complex lesion morphology or dissection. These data suggest that heparin provides satisfactory thrombin inhibition during routine angioplasty.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Angioplasty, Balloon, Coronary*
  • Anticoagulants / therapeutic use*
  • Antithrombin III / analysis
  • Atherectomy, Coronary*
  • Coronary Angiography
  • Coronary Disease / blood
  • Coronary Disease / diagnostic imaging
  • Coronary Disease / therapy*
  • Female
  • Fibrinopeptide A / analysis
  • Heparin / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Peptide Fragments / analysis
  • Peptide Hydrolases / analysis
  • Prothrombin / analysis
  • Thrombin / antagonists & inhibitors*
  • Thrombin / metabolism

Substances

  • Anticoagulants
  • Peptide Fragments
  • antithrombin III-protease complex
  • prothrombin fragment 1.2
  • Fibrinopeptide A
  • Antithrombin III
  • Prothrombin
  • Heparin
  • Peptide Hydrolases
  • Thrombin